联合用药对阵发性心房颤动患者疗效观察

目的 观察联合应用小剂量胺碘酮、螺内酯与厄贝沙坦对非瓣膜病阵发性心房颤动患者窦性心律的维持,对左心房内径、脑钠肽以及安全性的影响.方法 将142例非瓣膜病阵发性心房颤动按就诊顺序随机分为胺碘酮组(n=47),胺碘酮加螺内酯组(n=47),胺碘酮、厄贝沙坦、螺内酯组(联合用药组,n=48),3组均服用胺碘酮,胺碘酮加螺内酯组在应用胺碘酮基础上加用螺内酯,联合用药组在应用胺碘酮、螺内酯基础上加用厄贝沙坦,观察3组治疗6、12、18个月后的左心房内径、脑钠肽变化以及治疗3、6、12、18、24个月后的窦性心律维持率和安全性.结果 治疗6个月后3组左心房内径、脑钠肽值差异无统计学意义,但12个月后胺碘酮加螺内酯组、联合用药组的左心房内径、脑钠肽值明显小于胺碘酮组(P＜0.05),联合用药组左心房内径、脑钠肽值明显小于胺碘酮加螺内酯组(P＜0.05);治疗3、6个月后胺碘酮组窦性心律维持率低于胺碘酮加螺内酯组、联合用药组,治疗6个月后胺碘酮组和联合用药组之间差异有统计学意义(P＜0.05),治疗12个月后胺碘酮加螺内酯组、联合用药组的窦性心律维持率明显大于胺碘酮组(P＜0.05),联合用药组窦性心律维持率明显大于胺碘酮加螺内酯组(P＜0.05).结论 胺碘酮、螺内酯联合治疗非瓣膜病阵发性心房颤动维持实性心律的疗效优于单用胺碘酮,并能延缓左心房的扩大和脑钠肽值的升高,在胺碘酮、螺内酯基础上加用厄贝沙坦则使上述疗效进一步加强.

Abstract：

Objective To observe the effect and safety of amiodarone, spironolactone and irbesartan on sinus rhythm, left atrial internal diameter and brain natruretic peptide(BNP) for patients with nonvalvular paroxysmal atrial fibrillation(AF). Methods One hundred and forty-two patients with nonvalvular paroxysmal atrial fibrillation were divided into amiodarone group(n=47), amiodarone plus spironolactone group (n = 47 ) and amiodarone spironolactone plus irbesartan group ( Combined treatment group, n = 48 ). Three groups were treated with amiodarone.Amiodarone plus spironolactone group was treated with spironolactone in addition. Combined treatment group was treated with irbesartan based on amiodarone and spironolactone. Left atrial internal diameter and BNP were observed after 6 months, 12 months, 18 months respectively and the rate of maintenance of sinus rhythm was observed after 3months, 6 months, 12 months, 18 months, 24 months respectively. The safety of drugs was observed during this study. Results After 6 months treatments, left atrial internal diameter and BNP of three groups was no difference but left atrial internal diameter and BNP of amiodarone plus spironolactone group and Combined treatment group was less than that of amiodarone group after 12 months ( P ＜ 0.05 ). left atrial internal diameter and BNP of combined treatment group was less than those of amiodarone plus spironolactone group after 12 months ( P ＜ 0.05 ). After 3and 6 months treatments, the rate of maintenance of sinus rhythm of amiodarone group was lower than that in amiodarone plus spironolactone group and combined treatment group, but there was no statistically significance difference between amiodarone group and amiodarone plus spironolactone group, amiodarone plus spironolactone group andCombined treatment group. The rate of maintenance of sinus rhythmia of amiodarone group was statistically lower than that in combined treatment group (P＜0.05). After 12 months, The rate of mainterance of sinus rhythmia of amiodarone plus spironolactone group and Combined treatment group was more than that of amiodarone group (P＜0.05 ), and that of group Ⅲ was more than that of amiodarone plus spironolactone group ( P ＜ 0.05 ). Conclusions Therapeutic results of mainterance of sinus rhythmia is better with amiodarone plus spironolactone than with amiodarone lonely, and treatment with amiodarone plus spironolactone can suspend the enlargement of left atrial. This influence will strengthen if treated with irbesartan based on amiodarone and spironolactone.     

高血压患者左房内径变化对心房颤动的影响

目的:探讨原发性高血压患者的左心房内径变化对心房颤动的影响。方法:选取2019年1月～2020年5月入某院诊疗的原发性高血压患者156例,随机分组,其中52例为持续性房颤组,52例为阵发性房颤组,52例高血压无合并房颤患者为对照组,通过超声动态心电图检测左心房内径(Left atrial diameter, LAD)、左心室射血分数(Left ventricular ejection fraction, LVEF)。结果:持续性房颤组中LAD、LVEF、左心房增大发生率均高于阵发性房颤组和对照组,而阵发性房颤组的上述指标均高于对照组,差异具有统计学意义(P0.05)。结论:高血压房颤患者会出现左心房内径增大、左心室射血分数降低的趋势,表明左心房内径变化对心房颤动产生影响,且左心房内径变化与房颤的发生密切相关。     

心房颤动的药物治疗

心房颤动(atrial fibrillation,AF),简称"房颤",是一种十分常见的心律失常,其发病率随年龄的增长而增加.房颤根据其持续的时间可以分为阵发性房颤(paroxysmal AF)、持续性房颤(persistent AF)、永久性房颤(permanent AF)3大类[1],即3P分类法.不同的类型对选择治疗方法有重要意义.房颤的治疗包括药物治疗和非药物治疗两方面.在非药物治疗方面包括电复律、射频消融、外科迷宫术、起搏器植入等,特别是射频消融治疗为房颤的根治带来希望[2].但由于非药物治疗对医院技术条件的要求,所以目前对于基层医院而言药物治疗是临床最重要的选择.     

心房颤动患者左心房大小与缺血性脑卒中相关性分析

目的探讨心房颤动(atrial fibrillation,AF)患者左心房(left atrium,LA)大小与缺血性脑卒中的相关性。方法选取2015年6月~2016年10月在我院住院治疗的118例心房颤动患者,按有无缺血性脑卒中分成两组:A组(单纯房颤组):有房颤无缺血性脑卒中;B组(卒中组):有房颤合并缺血性脑卒中。记录患者年龄、性别、合并疾病、超声心动图指标等,一般资料进行单因素分析,多因素Logistic回归分析心房颤动发生缺血性脑卒中的危险因素。结果 A组与B组比较,两组左心房大小存在显著差异(P0.05),B组LA水平明显高于A组。左心房大小、高血压病史、糖尿病病史为缺血性脑卒中的独立危险因素。结论左心房增大是导致缺血性脑卒中的高危因素,临床上应给予积极干预,预防恶性事件的发生。     

依布利特和普罗帕酮治疗心房扑动和心房颤动的Meta分析

目的 评价依布利特和普罗帕酮治疗心房扑动(房扑)和心房颤动(房颤)的疗效和安全性.方法 通过检索历年中英文电子文献数据库和手工检索的方式,纳入符合标准的依布利特和普罗帕酮治疗房扑或房颤的所有随机对照试验,依次进行质量评价和资料提取,并进行Meta分析.结果 Meta分析显示:①房扑/房颤总转复率:依布利特(64.52%)高于普罗帕酮(42.37%),差异有统计学意义(OR 2.50,95%CI1.64～3.83,P＜0.01),漏斗图提示未见偏倚.②房颤转复率:依布利特(61.31%)高于普罗帕酮(41.61%),差异有统计学意义(OR 2.24,95%CI 1.38～3.64,P＜0.01),漏斗图提示未见偏倚.③房扑转复率:依布利特(82.69%)高于普罗帕酮(40.82%),差异有统计学意义(OR 6.53,95%CI2.65～16.10,P＜0.01),漏斗图提示未见偏倚.④不良反应发生率:两者不良反应率差异无统计学意义(P＞0.05).结论 与普罗帕酮相比,依布利特可以更有效地转复房扑和房颤,两者安全性上无明显差别.

Abstract：

Objective To evaluate the efficacy and safety of ibutilide and propafenone for treatment of atrial flutter(AFL) and atrial fibrillation(AF). Methods The random controlled trials (RCTs) concerning the ibutilide and propafenone in the treatment of atrial flutter or atrial fibrillation were collected in a meta-analysis. The Rev Man 5.0 software of Cochrane Coordination Net was used for statistical analysis. Results Meta-analysis showed that :①total cardioversion rate of ibutilide for AFL/AF (64.52%) was higher than that of propafenone(42. 37% ) ( P ＜0.05). No bias was prompted on the funnel plot. ②cardioversion rate of Ibutilide for AF (61.31%) was higher than that of propafenone(41.61% )( P ＜0.05). No bias was prompted on the funnel plot. ③cardioversion rate of Ibutilide for AFL ( 82.69% ) was higher than that of propafenone(40.82% ) ( P ＜ 0.05 ). No bias was prompted on the funnel plot. ④Adverse reaction rates showed no significant difference between the 2 medicine. Conclusion Compared with propafenone, ibutilide is more effective for the treatment of atrial flutter or atrial fibrillation, but the security of both drugs shows no significant difference.     

叶酸对急性心肌梗死合并心房颤动患者的疗效观察

目的 探讨叶酸对急性心肌梗死（acute myocardial infarction,AMI）合并阵发性心房颤动（atrial fibrillation,AF）患者的临床疗效.方法 AMI合并AF 60例,随机分为对照组和治疗组,各30例,对照组常规治疗,治疗组在对照组基础上口服叶酸（10 mg/次,3次/d）.结果 治疗组5 d转复率高于对照组（93.33% VS 66.67%）,差异有统计学意义（P＜0.05）;住院天数低于对照组[（10.97±2.31）d VS（16.21±3.40）d],差异有统计学意义（P＜0.05）;阵发性房颤复发率和转为持续性或永久性房颤的发生率低于对照组（6.67% VS 30.00%）,差异有统计学意义（P＜0.05）;缺血事件发生率低于对照组（16.67% VS 43.33%）,差异有统计学意义（P＜0.05）.结论 叶酸治疗AMI合并AF,既能够提高转复率,减少住院时间,又能降低房颤的复发与维持疗效,降低缺血事件的发生率.     

风湿性心脏病患者心包液和血液中心钠素与心功能的关系

目的 探讨心包液和血液中心钠素含量与风湿性心脏病患者心脏功能的关系.方法 风湿性心脏病需行瓣膜置换术患者33例,术中留取心包液和静脉血,利用放射免疫分析方法检测心包液和血浆中心钠素的含量,分析其与心功能的关系.结果 患者心包液中含有高浓度的心钠素,明显高于血浆中的水平[(0.61±0.49)μg/L比(0.45±0.18)μg/L,P=0.046];射血分数＜50%的患者心包液中心钠素的含量明显高于射血分数≥50%的患者[(0.98±0.81)μg/L比(0.48±0.18)μg/L].结论 人心包液中的心钠素可能和血液中的心钠素一样参与心功能的调节.

Abstract：

Objective To investigate the relationship between the cardiac function and the levels of atrial natriuretic peptide (ANP)in pericardial fluid and plasma in patients with rheumatic heart diseases. Methods The study involved 33 patients undergoing open heart surgery for either heart valvuloplasty or valve replacement. ANP concentrations in the plasma, pericardial fluid, and pericardial tissues were measured by using of radioimmunoassay (RIA). Results The level of ANP in human pericardial fluid was significantly higher than that in the plasma (0.614±0.486 ng/ml vs 0. 451 ±0. 184 ng/ml, P =0. 046). The ANP concentration in pericardial fluid of patients with left ventricular ejection fraction(LVEF) ＜ 50% was much higher than that of patients with LVEF ≥50%. Conclusion The ANP in the pericardial fluid may be involved in the deterioration of cardiac function in patients with rheumatic heart diseases.     

急性脑梗死患者血清脂联素和同型半胱氨酸与高敏C反应蛋白的临床研究

目的 探讨急性脑梗死(ACI)患者血清脂联素、同型半胱氨酸(Hcy)和高敏C反应蛋白(hs-CRP)水平的变化及临床意义.方法 选择ACI患者100例,按脑梗死体积及神经功能缺损程度分别分为3个亚组,选择同期健康体检者35例作为正常对照组.用酶联免疫吸附法检测血清脂联素和Hcy水平,应用免疫比浊法测定血清hs-CRP水平,并对结果进行比较.结果 ACI组血清脂联素水平(6.4±1.5)mg/L明显低于正常对照组的(12.5±2.3)mg/L,差异有统计学意义(P＜0.05);小梗死组(28例)、中梗死组(42例)、大梗死组(30例)患者血清脂联素水平[(8.8±1.9)、(5.6±1.3)、(2.7±0.8)mg/L]逐渐降低,轻型组(27例)、中型组(42例)、重型组(31例)患者[(8.5±1.7)、(5.4±1.1)、(2.5±0.7)mg/L]亦逐渐降低,差异均有统计学意义(均P＜0.05).ACI组血清Hcy和hs-CRP水平明显高于正常对照组,差异均有统计学意义(均P＜0.05);小梗死组、中梗死组、大梗死组患者血清Hcy和hs-CRP水平逐渐升高,轻型组、中型组、重型组患者亦逐渐升高,差异均有统计学意义(均P＜0.05).结论 血清脂联素、Hcy及hs-CRP参与了ACI的发病;并且它们的水平与脑梗死体积及神经功能缺损程度密切相关,检测这3个指标有助于对ACI患者病情及预后做出正确的判断.

Abstract：

Objective To investigate the clinical significance of serum levels of adiponectin (APN),homocysteine(Hcy) and high-sensitive C-reaction protein (hs-CRP) in patients with acute cerebral infarction(ACI).Methods One hundred patients with ACI were selected and divided into different groups according to the size of infarction and clinical neurologic impairment degree score. 35 healthy people were used as control group. APN and Hcy concentrations were detected by enzyme-linked immunosorbent assay (ELISA). The serum hs-CRP level was detected by immunoturbidimetry. Results The serum APN levels in the patients with ACI were significantly lower than those in the healthy subjects(P＜0.05). The serum levels of APN decreased steply with the volume of infarction;the serum levels of APN decreased steply with the clinical neurologic impairment degree score,the differences of APN levels between the groups were significant (all P＜0.05). The serum Hcy and hs-CRP levels in the patients with ACI were significantly higher than those in the healthy subjects(12.5 ± 2.3)mg/L(P＜0.05). The serum levels of Hcy and hs-CRP increased steply with the volume of infarction [(8.8 ± 1.9) mg/L,(5.6 ± 1.3) mg/L,(2.7 ±0.8)mg/L];the serum levels of Hcy and hs-CRP increased steply with the clinical neurologic impairment degree score [(8.5±1.7)mg/L,(5.4±1.1)mg/L,(2.5±0.7)mg/L],the differences of levels of Hcy and hsCRP between two groups were significant (all P＜0.05). Conclusions The APN,Hcy and hs-CRP may play an important role in the pathogenesis of ACI. The serum level of APN,Hcy and hs-CRP is closely correlated with the volume of infarction and the clinical neurologic impairment degree score,which may be of great value in predicting acute cerebral infarction and the severity of cerebral infarction.     

通补防颤方对Ach-CaCl_(2)诱导大鼠阵发性房颤的防治作用北大核心CSCD

目的探索通补防颤方对乙酰胆碱-氯化钙(Ach-CaCl_(2))诱导大鼠阵发性房颤(paroxysmal atrial fibrillation,PAF)的防治作用。方法将雄性SD大鼠随机分为空白对照组、模型组、通补防颤方低、中、高剂量组、胺碘酮组。采用尾静脉注射Ach-CaCl_(2)混合液建立PAF大鼠模型。通过心电图检测大鼠房颤易感性,电Mapping检测大鼠心房传导离散度,小动物超声仪检测大鼠左心房直径及左心房面积,Masson染色观察大鼠心房肌组织纤维情况,免疫组化和Western blot法检测大鼠酪氨酸羟化酶(tyrosine hydroxylase,TH)蛋白表达。结果Ach-CaCl_(2)尾静脉注射7 d后大鼠心电图表现为P波消失,代之以不规则的f波,RR间期绝对不规则;与模型组相比,通补防颤方低、中、高剂量组及胺碘酮组不同程度延长大鼠房颤诱发时间,缩短房颤持续时间;降低心房传导离散度;缩小左心房直径及左心房面积;改善心房肌组织排列,减少纤维沉积;降低TH蛋白平均分布密度及分布不均一程度;下调TH蛋白表达水平。结论通补防颤方可降低Ach-CaCl_(2)诱导PAF大鼠的房颤易感性、心房传导离散度,改善电重构、结构重构及神经重构,为通补防颤方在防治PAF的临床应用提供数据支撑,以期提高PAF的临床治疗水平。     

Eleutheroside B,a selective late sodium current inhibitor,suppresses atrial fibrillation induced by sea anemone toxin Ⅱ in rabbit hearts

Eleutheroside B(EB)is the main active constituent derived from the Chinese herb Acanthopanax senticosus(AS)that has been reported to possess cardioprotective effects.In this study we investigated the effects of EB on cardiac electrophysiology and its suppression on atrial fibrillation(AF).Whole-cell recording was conducted in isolated rabbit atrial myocytes.The intracellular calcium([Ca²⁺]i)concentration was measured using calcium indicator Fura-2/AM fluorescence.Monophasic action potential(MAP)and electrocardiogram(ECG)synchronous recordings were conducted in Langendorff-perfused rabbit hearts using ECG signal sampling and analysis system.We showed that EB dose-dependently inhibited late sodium current(INaL),transient sodium current(INaT),and sea anemone toxin II(ATX II)-increased INaL with IC50 values of 167,1582,and 181μM,respectively.On the other hand,EB(800μM)did not affect L-type calcium current(ICaL),inward rectifier potassium channel current(IK),and action potential duration(APD).Furthermore,EB(300μM)markedly decreased ATX II-prolonged the APD at 90%repolarization(APD90)and eliminated ATX II-induced early afterdepolarizations(EADs),delayed afterdepolarizations(DADs),and triggered activities(TAs).Moreover,EB(200μM)significantly suppressed ATX II-induced Na+-dependent[Ca2+]i overload in atrial myocytes.In the Langendorff-perfused rabbit hearts,application of EB(200μM)or TTX(2μM)substantially decreased ATX II-induced incidences of atrial fibrillation(AF),ventricular fibrillation(VF),and heart death.These results suggest that augmented INaL alone is sufficient to induce AF,and EB exerts anti-AF actions mainly via blocking INaL,which put forward the basis of pharmacology for new clinical application of EB.     

左旋氨氯地平对阵发性房颤并高血压患者左心结构及房颤的影响

目的观察左旋氨氯地平对阵发性房颤并高血压患者左房内径（LAD）、左室舒张末内径（LVEDD）、左室射血分数（LVEF）、房颤发作情况的影响。方法将阵发性房颤并高血压患者100例随机分为治疗组（n=50）和对照组（n=50）。降压药物治疗组给予左旋氨氯地平,对照组给予坎地沙坦,随访1年,观察治疗前后LAD、LVEDD、LVEF、房颤发作情况。结果至随访结束,在长期应用胺碘酮的患者中,对照组房颤复发17例,占81.0%,治疗组房颤复发22例,占95.7%,两组之间没有差别（χ2=1.122,P〉0.05）。未长期应用胺碘酮的患者,对照组、治疗组在7～12个月时房颤发作次数均较治疗前减少（t=2.823,P〈0.01;t=2.655,P〈0.05）,两组之间没有差异（t=0.594,P〉0.05）。与治疗前比较,对照组、治疗组的LAD、LVEDD均降低、LVEF增加（t=2.421～3.814,P〈0.05）,治疗后两组之间的LAD、LVEDD、LVEF比较,差别无统计学意义（F=0.029～3.644,P〉0.05）。结论左旋氨氯地平和坎地沙坦均可减少阵发性房颤并高血压患者房颤的复发,降低LAD、LVEDD,升高LVEF,两者之间没有差异。     

经导管射频消融术对有症状性心房颤动患者心功能的影响

目的 探讨经导管射频消融术对有症状性心房颤动患者心功能的影响.方法 选取本院2012年7月至2015年9月收治的有症状性心房颤动(AF)患者110例,最终入选有95例,按照不同治疗方式分为药物治疗组(31例)与经导管射频消融术组(RFCA,64例),术后3个月对两组患者行左房内径(LAD)、左心室舒张末期内径(LVEDd)、左心室射血分数(LVEF)等心功能指标,并采用生活质量量表SF-36对患者生活质量进行评分,比较结果.结果 治疗后3个月,两组患者较治疗前LAD显著缩小,LVEDd显著增加,且组间差异均有统计学意义(均P＜0.05),两组LVEF比较无明显变化(P＞0.05);治疗后两组患者生活质量均显著提高,且RFCA组明显高于药物治疗组(均P＜ 0.05).结论 经导管消融术可有效改善房颤患者左心房功能,维持窦性心律,值得临床应用.     

格列本脲对糖尿病大鼠心房重构及心房颤动诱发的影响

目的　探究格列本脲（GLB）对糖尿病（DM）大鼠心房重构及心房颤动（AF）诱发的影响。方法　将48只SD大鼠按随机数字表法分为3组：对照组（Ctl组）、糖尿病组（DM组）和糖尿病+格列本脲组（GLB组），每组16只。采用链脲佐菌素法建立DM动物模型，GLB组大鼠每日灌胃服用GLB（10 mg/kg），动物于相同条件下饲喂6周，记录第6周空腹血糖及体质量。6周后进行心脏超声检查，记录舒张早期波峰值速度（E）、舒张晚期波峰值速度（A）、左心房内径、左心室射血分数、左心室短轴缩短率、E/A、肺动脉血流加速时间、平均肺动脉压、收缩与舒张期室间隔、左心室内径和左心室后壁厚度；无创血压计检测大鼠心率、收缩压和舒张压，计算平均动脉压。在体电生理实验检测大鼠房室文氏周长、窦房结恢复时间、有效不应期、AF诱发率；心外膜激活映射标测实验检测绝对不均匀指数与传导相对异质性、心外膜传导速度；Masson染色检测左心房间质纤维化，计算胶原容积分数（CVF）。结果　与DM组相比，GLB组心脏体质量比、心室体质量比降低，左心房内径减小（P＜0.05）。DM组较Ctl组心外膜传导速度降低，传导相对异质性增加；与DM组相比，GLB组心外膜传导速度提高（P＜0.05），传导相对异质性差异无统计学意义。GLB组较DM组R-R间期缩短，AF诱发率下降（P＜0.05）。GLB组和DM组较Ctl组心房肌纤维化程度加重，CVF增大（P＜0.05）。GLB组较DM组心房肌纤维化程度减轻，CVF减小（P＜0.05）。结论　DM可促进大鼠心房组织纤维化，与AF发病有关，GLB可以通过延缓DM大鼠心肌组织纤维化进展来降低AF诱发率。     

心房颤动患者经心脏导管射频消融术后心脑血管事件发生的危险因素分析

目的 研究心房颤动患者经心脏导管射频消融术后心脑血管事件发生的危险因素.方法 选取本院2012年2月至2016年2月134例心房颤动患者为研究对象,所有患者均采用经心脏导管射频消融术治疗,根据射频消融术后6个月心脑血管事件的发生情况,将纳入患者分为观察组(n=51)和对照组(n=83),对两组的临床资料进行对比.结果 观察组的年龄、BMI、心肌病、脑卒中史、左心房直径、左室射血分数等6个因素与对照组比较差异均有统计学意义(均P＜ 0.05).结论 积极控制年龄、BMI、心肌病、脑卒中史、左心房直径、左室射血分数等危险因素,有利于降低心房颤动患者经心脏导管射频消融术后心脑血管事件发生的风险.     

稳心颗粒联合胺碘酮和培哚普利治疗老年阵发性心房颤动的临床效果及安全性

目的 研究稳心颗粒联合胺碘酮和培哚普利治疗老年阵发性心房颤动的临床效果和安全性.方法 心内科治疗的老年阵发性心房颤动患者116例,随机分为对照组和观察组,每组58例.对照组使用胺碘酮联合培哚普利治疗,观察组有对照组的基础上加用稳心颗粒治疗.比较2组患者治疗后的效果和不良反应等.结果 观察组有效率为90.57％,对照组有效67.27％,2组差异有统计学意义(P＜0.05).2组心率、房颤次数、左心室舒张末内径(LVEDD)、左心房内径(LAd)、左心房最大容积(LAVmax)、P波最大时限(Pmax)、P波离散度(Pd)、A峰峰值流速(VA),治疗前差异无统计学意义(P＞0.05),治疗后,观察组与治疗前差异有统计学意义(P＜0.05),对照组除左心房内径(LAd)之外与治疗之前差异均有统计学意义(P＜0.05).观察组不良反应3例,不良反应发生率为5.45％,对照组不良反应15例,不良反应发生率为28.30％,差异有统计学意义(P＜0.05).结论 使用稳心颗粒联合胺碘酮和培哚普利治疗老年阵发性心房颤动的效果较为明确并且优于一般的临床治疗效果,安全性高,值得进一步研究分析和应用.     

扩张型心肌病患者血尿酸水平与心房颤动的关系

目的 探讨扩张型心肌病(DCM)患者血尿酸水平与心房颤动(房颤)发生的关系以及临床意义.方法 回顾性分析2010年1月至2011年12月在我院住院治疗的DCM患者的临床资料,比较房颤组(48例)与非房颤组(129例)年龄、心功能分级、血尿酸水平、左心房内径、左心室舒张末内径、左心室射血分数、室间隔厚度、左心室后壁厚度的差异.按尿酸水平分为升高组(88例)与正常组(89例)后比较房颤发生率,并分析尿酸水平对于房颤发生的影响.结果 与非房颤组比较,房颤组患者年龄较大[(64±13)岁比(59±15)岁,P＜0.05],血尿酸水平明显升高[(491±135)μmol/L比(424±121) μmol/L,P＜0.01],左心房内径明显增大[ (48 ±8)mm比(43 ±5)mm,P＜0.01];血尿酸升高组患者房颤的发生率较正常组高[34.1％ (30/88)比20.2％ (18/89),P＜0.05];血尿酸水平(OR:1.003,95％ CI:1.000 ～1.006,P＜0.05)和左心房内径(OR:1.147,95％ CI:1.076～1.224,P＜0.01)是DCM患者发生房颤的独立危险因素.结论 血尿酸水平是DCM患者发生房颤的独立危险因素,可以作为DCM患者发生房颤的预测指标.     

缬沙坦和美托洛尔联合治疗慢性心功能不全患者阵发性心房颤动

目的探讨缬沙坦和美托洛尔对慢性心功能不全患者阵发性心房颤动的影响。方法将138例慢性心功能不全患者阵发性房颤随机分为：胺碘酮组（Ⅰ组）、胺碘酮＋缬沙坦组（Ⅱ组）、胺碘酮＋美托洛尔组（Ⅲ组）、胺碘酮＋缬沙坦＋美托洛尔组（Ⅳ组）,治疗随访2年,比较四组治疗前后左心房内径,窦性心律维持率。结果 （1）Ⅰ组和Ⅲ组左心房内径均大于Ⅱ组和Ⅳ（P〈0.05）,而Ⅰ组和Ⅲ、Ⅱ和Ⅳ组的比较差异无统计学意义。（2）Ⅰ、Ⅱ、Ⅲ、Ⅳ组的窦性心律维持率Ⅰ组低于Ⅱ、Ⅲ和Ⅳ组（P〈0.05）。结论缬沙坦和美托洛尔联合治疗能减少慢性心力衰竭患者阵发性心房颤动的复发,缬沙坦和美托洛尔联合治疗可显著减慢左房的扩大。     

P波离散度对高血压患者并发心房颤动的预测价值

目的：探讨P波离散度在高血压患者阵发性心房颤动发生中的预测价值。方法：将95例高血压患者按有无房颤分为两组,采用同步12导联体表心电图测量Pmax、Pmin和Pd,超声心动图测定左心房内径（LAD）和左心室射血分数（LVEF）,比较两组间Pmax、Pmin、Pd、LAD和LVEF的差异。结果：与对照组相比,观察组Pmax和Pd明显增大（P〈0.05）,两组间Pmin、LAD和LVEF差异无统计学意义（P〉0.05）,Pmax〉110ms＋Pd≥40ms预测房颤的敏感性及阴性预测值有所下降,但特异性和阳性预测值上升。结论：Pd是高血压合并阵发性房颤的预测因子,与Pmax联合应用预测价值更高。     

盐酸胺碘酮联合盐酸贝那普利治疗阵发性房颤的临床观察

目的探讨盐酸胺碘酮联合盐酸贝那普利治疗阵发性心房颤动(房颤)的临床疗效。方法将63例发作频繁的阵发性房颤患者随机分为研究组33例和对照组30例。对照组在规范治疗原发病及有效抗凝治疗基础上单用盐酸胺碘酮治疗;研究组在对照组治疗基础上加用盐酸贝那普利治疗。2组均治疗随访12个月,比较2组临床疗效和治疗前、后左心房内径。结果研究组总有效率为93.9%,高于对照组的76.6%,且治疗后左心房内径小于治疗前和对照组,差异均有统计学意义(P<0.05)。结论盐酸胺碘酮联合盐酸贝那普利治疗阵发性房颤,对预防房颤的复发和持续性房颤的发生疗效显著,并能缩短左心房内径,延缓左心房扩大,临床疗效优于单用盐酸胺碘酮。